Your browser doesn't support javascript.
loading
Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
Pearson, Andrew Dj; Rossig, Claudia; Mackall, Crystal; Shah, Nirali N; Baruchel, Andre; Reaman, Gregory; Ricafort, Rosanna; Heenen, Delphine; Bassan, Abraham; Berntgen, Michael; Bird, Nick; Bleickardt, Eric; Bouchkouj, Najat; Bross, Peter; Brownstein, Carrie; Cohen, Sarah Beaussant; de Rojas, Teresa; Ehrlich, Lori; Fox, Elizabeth; Gottschalk, Stephen; Hanssens, Linda; Hawkins, Douglas S; Horak, Ivan D; Taylor, Danielle H; Johnson, Courtney; Karres, Dominik; Ligas, Franca; Ludwinski, Donna; Mamonkin, Maksim; Marshall, Lynley; Masouleh, Behzad K; Matloub, Yousif; Maude, Shannon; McDonough, Joe; Minard-Colin, Veronique; Norga, Koen; Nysom, Karsten; Pappo, Alberto; Pearce, Laura; Pieters, Rob; Pule, Martin; Quintás-Cardama, Alfonso; Richardson, Nick; Schüßler-Lenz, Martina; Scobie, Nicole; Sersch, Martina A; Smith, Malcolm A; Sterba, Jaroslav; Tasian, Sarah K; Weigel, Brenda.
Afiliação
  • Pearson AD; ACCELERATE, Europe. Electronic address: andy1pearson@btinternet.com.
  • Rossig C; University Children´s Hospital Muenster, Pediatric Hematology and Oncology, Germany.
  • Mackall C; Department of Pediatrics and Medicine, Stanford University, Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford, CA, USA.
  • Shah NN; Pediatric Oncology Branch, National Cancer Institute, USA.
  • Baruchel A; Hôpital Universitaire Robert Debré (APHP) and Université de Paris, France.
  • Reaman G; US Food and Drug Administration, USA.
  • Ricafort R; Bristol Myers Squibb Company/Celgene, a BMS Company, USA.
  • Heenen D; KickCancer, Belgium.
  • Bassan A; Syncopation Life Sciences, USA.
  • Berntgen M; Scientific Evidence Generation Department, Human Medicines Division, European Medicines Agency (EMA), Amsterdam, Netherlands.
  • Bird N; Solving Kids' Cancer, UK.
  • Bleickardt E; Novartis, USA.
  • Bouchkouj N; US Food and Drug Administration, USA.
  • Bross P; US Food and Drug Administration, USA.
  • Brownstein C; Cellectis, USA.
  • Cohen SB; CRISPR Therapeutics, Switzerland.
  • de Rojas T; ACCELERATE, Europe.
  • Ehrlich L; US Food and Drug Administration, USA.
  • Fox E; St Jude Children's Research Hospital, USA.
  • Gottschalk S; St Jude Children's Research Hospital, USA.
  • Hanssens L; Miltenyi Biomedicine, Germany.
  • Hawkins DS; Seattle Children's Hospital, USA.
  • Horak ID; Tessa Therapeutics, Singapore.
  • Taylor DH; Paediatric Oncology Reference Team (PORT), London, UK.
  • Johnson C; US Food and Drug Administration, USA.
  • Karres D; Paediatric Medicines Office, Scientific Evidence Generation Department, Human Medicines Division, European Medicines Agency (EMA), Amsterdam, Netherlands.
  • Ligas F; Paediatric Medicines Office, Scientific Evidence Generation Department, Human Medicines Division, European Medicines Agency (EMA), Amsterdam, Netherlands.
  • Ludwinski D; Solving Kids' Cancer, USA.
  • Mamonkin M; Baylor College of Medicine, USA.
  • Marshall L; The Royal Marsden Hospital and the Institute of Cancer Research, London, UK.
  • Masouleh BK; Kite, a Gilead Company, USA.
  • Matloub Y; Takeda Pharmaceuticals International, USA.
  • Maude S; Children's Hospital of Philadelphia and University of Pennsylvania School of Medicine, Philadelphia, USA.
  • McDonough J; The Andrew McDonough B+ Foundation, USA.
  • Minard-Colin V; Department of Pediatric and Adolescent Oncology, INSERM U1015, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
  • Norga K; Antwerp University Hospital, Paediatric Committee of the European Medicines Agency, Federal Agency for Medicines and Health Products, Belgium.
  • Nysom K; Rigshospitalet, Denmark.
  • Pappo A; St Jude Children's Research Hospital, USA.
  • Pearce L; GlaxoSmithKline, USA.
  • Pieters R; Princess Maxima Center for Pediatric Oncology, Netherlands.
  • Pule M; Autolus Limited, UK.
  • Quintás-Cardama A; TCR(2) Therapeutics, USA.
  • Richardson N; US Food and Drug Administration, USA.
  • Schüßler-Lenz M; Chair of CAT (Committee for Advanced Therapies), European Medicines Agency (EMA), Amsterdam, Netherlands; Paul-Ehrlich-Institut, Germany.
  • Scobie N; Zoe4Life, Switzerland.
  • Sersch MA; Gracellbiotechnologies Inc, China.
  • Smith MA; National Cancer Institute, USA.
  • Sterba J; University Hospital Brno, Masaryk University, Brno, Czech Republic.
  • Tasian SK; Children's Hospital of Philadelphia and University of Pennsylvania School of Medicine, Philadelphia, USA.
  • Weigel B; University of Minnesota, USA.
Eur J Cancer ; 160: 112-133, 2022 01.
Article em En | MEDLINE | ID: mdl-34840026
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Receptores de Antígenos de Linfócitos T / Desenvolvimento de Medicamentos / Receptores de Antígenos Quiméricos / Oncologia Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Adolescent / Child / Humans País/Região como assunto: America do norte / Europa Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Receptores de Antígenos de Linfócitos T / Desenvolvimento de Medicamentos / Receptores de Antígenos Quiméricos / Oncologia Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Adolescent / Child / Humans País/Região como assunto: America do norte / Europa Idioma: En Ano de publicação: 2022 Tipo de documento: Article